Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Clancy

Showing results (11-20 of 226) with videos related to

Pageof 23
Sort By:
Expert Opinion on Orphan Drugs|January 3, 2017
CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on IvacaftorElizabeth L Kramer, John P Clancy
Drugs of Today (Barcelona, Spain : 1998)|April 26, 2013
Ivacaftor: the first therapy acting on the primary cause of cystic fibrosisG L McPhail, J P Clancy
Hand Clinics|May 11, 2013
Current flexor and extensor tendon motion regimens: a summarySean P Clancy, Daniel P Mass
Expert Opinion on Therapeutic Targets|November 24, 2017
TGFβ as a therapeutic target in cystic fibrosisElizabeth L Kramer, John P Clancy
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 25, 2009
Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in developmentSteven M Rowe, John P Clancy
Current Opinion in Pediatrics|November 14, 2006
Advances in cystic fibrosis therapiesSteven M Rowe, John P Clancy
Annual Review of Genomics and Human Genetics|February 25, 2016
Cystic Fibrosis and Its Management Through Established and Emerging TherapiesDavid R Spielberg, John P Clancy
The Journal of Clinical Psychiatry|March 1, 1992
Anabolic steroid use among substance abusers in treatmentG P Clancy, W R Yates
Academic Medicine : Journal of the Association of American Medical Colleges|October 17, 2013
Going "all in" to transform the Tulsa community's health and health care workforceGerard P Clancy, F Daniel Duffy
Internal Medicine Review (Washington, D.C. : Online)|February 25, 2017
Dynamics of Disease Progression and Gastrostomy Tube Placement in Children and Adolescents with Cystic Fibrosis: Application of Joint Models for Longitudinal and Time-to-Event DataRhonda Szczesniak, Weiji Su, J P Clancy
Pageof 23

Showing results (11-20 of 226) with videos related to

Sort By:
Pageof 23
Expert Opinion on Orphan Drugs|January 3, 2017
CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on IvacaftorElizabeth L Kramer, John P Clancy
Drugs of Today (Barcelona, Spain : 1998)|April 26, 2013
Ivacaftor: the first therapy acting on the primary cause of cystic fibrosisG L McPhail, J P Clancy
Hand Clinics|May 11, 2013
Current flexor and extensor tendon motion regimens: a summarySean P Clancy, Daniel P Mass
Expert Opinion on Therapeutic Targets|November 24, 2017
TGFβ as a therapeutic target in cystic fibrosisElizabeth L Kramer, John P Clancy
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 25, 2009
Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in developmentSteven M Rowe, John P Clancy
Current Opinion in Pediatrics|November 14, 2006
Advances in cystic fibrosis therapiesSteven M Rowe, John P Clancy
Annual Review of Genomics and Human Genetics|February 25, 2016
Cystic Fibrosis and Its Management Through Established and Emerging TherapiesDavid R Spielberg, John P Clancy
The Journal of Clinical Psychiatry|March 1, 1992
Anabolic steroid use among substance abusers in treatmentG P Clancy, W R Yates
Academic Medicine : Journal of the Association of American Medical Colleges|October 17, 2013
Going "all in" to transform the Tulsa community's health and health care workforceGerard P Clancy, F Daniel Duffy
Internal Medicine Review (Washington, D.C. : Online)|February 25, 2017
Dynamics of Disease Progression and Gastrostomy Tube Placement in Children and Adolescents with Cystic Fibrosis: Application of Joint Models for Longitudinal and Time-to-Event DataRhonda Szczesniak, Weiji Su, J P Clancy
Pageof 23